SCHEDULE: Mink Brook Partners Discloses Stake in Ekso Bionics

Mink Brook Partners LP, along with affiliated entities and William Mueller, has reported beneficial ownership of 190,596 shares, representing 5.4% of Ekso Bionics Holdings, Inc. common stock.

Summary

• Mink Brook Partners LP, Mink Brook Capital GP LLC, William Mueller, and Mink Brook Asset Management LLC have jointly filed a Schedule 13G.
• The filing indicates beneficial ownership of 190,596 shares of Ekso Bionics Holdings, Inc. common stock.
• This holding represents 5.4% of the company's outstanding common stock, based on 3,563,381 shares outstanding as of February 23, 2026.
• Mink Brook Partners LP is the primary holder, while Mink Brook Capital GP LLC, William Mueller, and Mink Brook Asset Management LLC may be deemed to have shared voting and dispositive power over these shares.
• The filing explicitly disclaims beneficial ownership beyond any pecuniary interest for William Mueller and Mink Brook Capital GP LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It provides important transparency regarding ownership but lacks operational or financial details that would indicate a positive or negative shift in the company's prospects.

Positives

• Disclosure of a significant ownership stake (5.4%) by Mink Brook Partners LP and its affiliates, which can indicate investor confidence.
• The filing is current and adheres to regulatory requirements, providing transparency to the market.

Negatives

• The filing does not contain financial performance data or operational updates, limiting insight into the company's current health.
• The disclaimer regarding beneficial ownership for certain parties may create ambiguity for some investors.

Risks

• The filing does not explicitly mention any risks associated with Ekso Bionics Holdings, Inc. or the investment itself.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Mueller or Mink Brook Capital GP LLC is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds accumulating significant stakes in publicly traded companies. This filing indicates a notable investment by Mink Brook Partners LP in the exoskeletal technology sector, a field with potential for growth but also facing challenges in market adoption and regulatory approval.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant ownership stake may influence investor sentiment and trading activity.
• Management: The disclosure may prompt management to engage with Mink Brook Partners LP regarding their investment thesis and company strategy.

Next Steps

• Monitor future filings from Mink Brook Partners LP and Ekso Bionics Holdings, Inc. for any changes in ownership or strategic developments.
• Observe Ekso Bionics Holdings, Inc.'s operational and financial performance for insights into the company's trajectory.

Key Dates

Keywords

Ekso Bionics Holdings, Schedule 13G, Mink Brook Partners LP, Beneficial Ownership, Common Stock, SEC Filing, Investment, Ownership Stake